MedTrace Logo

Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines

NCT03155100 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-09-26

No results posted yet for this study

Summary

The main aim of this study is to assess the ORR with a new drug combination, carfilzomib (CAR) + elotuzumab (ELO) + dexamethasone (CAR-ELO-Dex).

Conditions

  • Multiple Myeloma in Relapse

Interventions

DRUG

Carfilzomib for Inj 60 milligram (MG)

All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone

DRUG

Elotuzumab 400 MG

All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone

DRUG

Dexamethasone

All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Hospital District of Helsinki and Uusimaa

    collaborator OTHER

  • Raija Silvennoinen

    lead OTHER

Principal Investigators

  • Raija Silvennoinen, MD, PhD · Helsinki University Central Hospital CCC Hematology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-07
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • Finland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03155100 on ClinicalTrials.gov